Cointime reports: Zai Lab reported third-quarter total revenue of $108.2 million, with product revenue at $107.6 million, down 7% year over year but up 2% quarter over quarter. The sequential improvement came mainly from broader coverage and market penetration of core products and incremental sales from the launch of xanomeline trospium chloride, partly offset by lower tumor treating fields revenue.
Zai Lab Q3 revenue $108.2M, product sales down 7% YoY
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
6m ago
S&P 500 Falls 2.0% to 7,498.13
6m ago
Nasdaq falls 3.3% as AI stocks sell off on Democratic midterm sweep
7m ago
US memory chip stocks extend selloff; SanDisk plunges over 17%
36m ago
Nvidia Falls 5.6%, Hitting Intraday Low Since April
43m ago
SanDisk, Western Digital, Seagate all fall over 11%; AMD drops 11%
44m ago
Tesla and SpaceX Shares Both Tumble on November 5